(Latanoprost + netarsudil mesylate) is a Small Molecule owned by Aerie Pharmaceuticals, and is involved in 5 clinical trials, of which 4 were completed, and 1 is ongoing.

AR-13324 inhibits both Rho Kinase (ROCK) and the Norepinephrine Transporter (NET) which increases fluid outflow and reduces fluid inflow. ROCK is a type of protein kinase that regulates actin and myosin which are proteins that are responsible for cellular contraction. In the trabecular outflow pathway of the eye, the resistance to fluid outflow that maintains normal intraocular pressure (IOP) is regulated by the contraction of trabecular meshwork (TM) cells and the production of extracellular matrix. ROCK inhibitors block TM cell contraction and reduce the production of extracellular matrix, thereby increasing fluid outflow and thus decreasing IOP. Latanoprost is a prostanoid selective FP receptor agonist that reduces the IOP by increasing the outflow of aqueous humor.

The revenue for (Latanoprost + netarsudil mesylate) is expected to reach a total of $1.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Latanoprost + netarsudil mesylate) NPV Report.

(Latanoprost + netarsudil mesylate) is currently owned by Aerie Pharmaceuticals. Santen Pharmaceutical is the other company associated in development or marketing of (Latanoprost + netarsudil mesylate).

(Latanoprost + netarsudil mesylate) Overview

Latanoprost and Netarsudil mesylate (Rocklatan/ Roclanda) is a fixed dose combination, acts as an anti-glaucoma agent. It is formulated as solution drops for ophthalmic route of administration. Rocklatan is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

It is under development for the reduction of intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Netarsudil (AR-13324) acts by targeting both Rho kinase (ROCK) and the norepinephrine transporter (NET). Latanoprost acts by prostaglandin F receptor (FP receptor).

Aerie Pharmaceuticals Overview

Aerie Pharmaceuticals (Aerie) is a pharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. The company’s product comprise rhopressa, a once-daily eye drop that is used for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; and roclatan, a fixed-dose combination of rhopressa and latanoprost. Aerie works in partnership with other pharma companies and universities for drug discovery technologies. The company has presence in the US, UK and Ireland. Aerie is headquartered in Durham, North Carolina, the US.

The company reported revenues of (US Dollars) US$194.1 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$83.1 million in FY2020. The operating loss of the company was US$46.4 million in FY2021, compared to an operating loss of US$155.7 million in FY2020. The net loss of the company was US$74.8 million in FY2021, compared to a net loss of US$183.1 million in FY2020. The company reported revenues of US$33.3 million for the second quarter ended June 2022, an increase of 11.7% over the previous quarter.

Quick View – (Latanoprost + netarsudil mesylate)

Report Segments
  • Innovator (Non-NME)
Drug Name
  • (Latanoprost + netarsudil mesylate)
Administration Pathway
  • Ophthalmic
Therapeutic Areas
  • Ophthalmology
Key Companies
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.